MAZE at a glance
Maze Therapeutics, Inc. (MAZE, SEC CIK 1842295) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2024 (FY2024), Maze Therapeutics, Inc. (MAZE) reported revenue of $167.5 million and net income of $52.2 million. Diluted EPS was $1.25.
- As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Maze Therapeutics, Inc. (MAZE) shares worth $365.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Coloma Jason V on November 2, 2026 of 26,563 shares at $30.09 per share.
- In the last 90 days, MAZE insiders reported 0 open-market purchases ($0) and 30 open-market sales ($5.8M) on Form 4, a net sale of $5.8M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2024
- $167.5M
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 30 sells
- Net −$5.8M
- 13F holders
- 24 funds
- $365.3M · −1 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY; nine-month license revenue $20.0M vs $0
- Operating margin -107.3% vs -112.9% YoY, based on operating losses of $51.5M and $33.0M
- MZE829 R&D spending $7.1M, MZE782 $5.6M, up $2.8M and $3.5M YoY
- Cash, equivalents and marketable securities $477.0M; operating cash use $87.0M for nine months
- Outlook: additional capital needed; MZE782 PKU data expected 2027 and MZE829 pivotal trial planned first half 2027
Risk Factors
- Newly emphasized supply-chain risk: BIOSECURE Act signed December 2025 could restrict WuXi relationships if designated a biotechnology company of concern
- Regulatory risk: CMS GLOBE model begins January 1, 2027, potentially requiring incremental Medicare Part B rebates tied to international prices
- Clinical risk: MZE782 Phase 2 PKU trial initiated August 2026, with topline data expected in 2027
- Operational risk: MZE829 pivotal trial planned first half of 2027, subject to regulatory feedback
- Financial risk: $477.0 million cash, cash equivalents and marketable securities expected to fund operations for at least one year
AI summary of the MAZE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q3 net loss widened to $48.0M, or $0.79 per share, from $30.1M, reflecting accelerated clinical investment
- Cash, equivalents and marketable securities reached $477.0M, supporting projected operations into 2029
Item 3.02: Unregistered Sales of Equity Securities
- Maze exchanged 2,776,007 common shares for pre-funded warrants exercisable at $0.001 per share
- Outstanding shares decreased to 53,931,889 after the exchange, reducing immediately outstanding equity
Item 1.01: Entry into a Material Definitive Agreement
- Item 1.01 points investors to Item 3.02 for the substantive transaction details
- Material agreement implications depend on the securities issuance or funding terms described under Item 3.02
Item 7.01: Regulation FD Disclosure
- Dr. Johnson and Dr. Kornowski appointed to Maze Therapeutics’ Board
- Board additions may influence governance, strategic direction and oversight
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board additions: Paula A. Johnson and Sophie Kornowski appointed as Class III and Class I directors, respectively
- Dr. Kornowski joins audit and compensation committees, strengthening biopharma, investment and business-development expertise
Item EX-99.1: Item EX-99.1
- Paula Johnson and Sophie Kornowski appointed to Maze’s Board, strengthening clinical, biopharmaceutical, partnering, and M&A expertise
- MZE829 additional AMKD data expected in late 2026 or early 2027
AI summaries of MAZE 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MAZE
Don't miss the next MAZE filing
- Alerts as it files. A push when MAZE files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MAZE, by share count.
- Ask anything. An AI agent that reads every MAZE filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Coloma Jason V | Sell | Nov 2, 2026 | 26,563 | $30.09 |
| Coloma Jason V | Sell | Nov 2, 2026 | 5,345 | $31.05 |
| Coloma Jason V | Sell | Nov 2, 2026 | 2,257 | $30.12 |
| Coloma Jason V | Sell | Nov 2, 2026 | 336 | $30.91 |
| Dandekar Atul | M | Oct 29, 2026 | 6,643 | $10.42 |
| Dandekar Atul | M | Oct 29, 2026 | 857 | - |
| Dandekar Atul | M | Oct 29, 2026 | 857 | $10.42 |
| Dandekar Atul | Sell | Oct 29, 2026 | 7,500 | $32.07 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $167.5M | - |
| Operating Income | - | $57.6M | -$142.9M |
| Net Income | - | $52.2M | -$131.1M |
| Op. Margin | - | 34.4% | - |
| Net Margin | - | 31.2% | - |
| Balance Sheet | |||
| Total Assets | - | $240.5M | $397.1M |
| Equity | -$373.8M | -$311.2M | $355.0M |
| ROE | - | -16.8% | -36.9% |
| Per Share | |||
| EPS | - | $1.25 | $-3.05 |
| Cash Flow | |||
| Operating CF | - | $76.0M | -$111.9M |
| CapEx | - | $1.1M | $794K |
Source: XBRL data in Maze Therapeutics, Inc. (MAZE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate MAZE share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 24 | $365.3M |
| Q2 2026 | 25 | $384.3M |
| Q1 2026 | 29 | $284.2M |
| Q4 2025 | 25 | $349.2M |
| Q3 2025 | 19 | $178.0M |
| Q2 2025 | 14 | $53.5M |
| Q1 2025 | 14 | $47.4M |
- Citadel Advisors LLC+727.1K (+85%)
- Goldman Sachs Group+553.5K (+189%)
- JPMorgan Chase & Co+250.9K (+26%)
- BlackRock+209.8K (+6%)
- State Street Corp+124.6K (+12%)
- Ameriprise Financial−161.2K (-71%)
- Bank of America Corp−127.0K (-40%)
- Vanguard Portfolio Management LLC−76.1K (-19%)
- Two Sigma Investments−38.6K (-20%)
- Morgan Stanley−35.1K (-26%)
- Dimensional Fund Advisors+100.6K
- Prudential Financial+9.1K
- FMR LLC (Fidelity)−1.06M
- Raymond James Financial−66.4K
- D.E. Shaw & Co−12.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 150 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MAZE filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Oct 30, 2026 | - | - | - |
| 8-K | Oct 16, 2026 | - | Analysis | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 5, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
MAZE SEC filings: frequently asked questions
Are MAZE insiders buying or selling?
In the last 90 days, Maze Therapeutics, Inc. (MAZE) officers, directors and 10% owners reported no open-market purchases and 30 open-market sales worth $5.8 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MAZE stock?
As of September 30, 2026, the largest Maze Therapeutics, Inc. (MAZE) holders among the 13F filers tracked by SignalX were BlackRock ($100.9 million), Vanguard Capital Management LLC ($51.1 million), Citadel Advisors LLC ($42.9 million), Alphabet Inc ($37.7 million), JPMorgan Chase & Co ($32.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MAZE's revenue in fiscal year 2024?
For the fiscal year ended December 31, 2024 (FY2024), Maze Therapeutics, Inc. (MAZE) reported revenue of $167.5 million and net income of $52.2 million. Diluted EPS was $1.25. The figures come from the XBRL data in the 10-K.
What did MAZE report in its latest 8-K?
Maze Therapeutics, Inc. (MAZE) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.
What are the latest MAZE SEC filings?
Maze Therapeutics, Inc. (MAZE) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 4, 2026.
What is MAZE's SEC CIK number?
Maze Therapeutics, Inc. (MAZE)'s SEC Central Index Key (CIK) is 1842295. EDGAR lists every MAZE filing under that number.
Ask anything about MAZE
The research agent reads MAZE's filings, financials, insider trades and 13F holders, then answers with sources.